Pharmaceutical group focused on the development of medicines for the treatment of neuro-developmental disorders
Schroder Investment Management: 10%
Cazenove Capital: 8.5%
Michael Hudson: 12.5%
Insight Investments Management (Global): 10%
Lloyds: 9.6%
| 2008 | 2007 | |
|---|---|---|
| Turnover: | n/a | n/a |
| Pre-tax profit: | £ (4.94m) | £ (3.23m) |
| EPS: | (13.3) p | (16.6) p |
Collaboration for Neuropharm 20/09/2007
Advertisement
The new survey into new AIM companies focusing on IPO activity over the closing months of 2008. The report itself contains information on the brokers who are most able to raise cash in the current environment and the sectors that are attracting institutional investment. Buy the new issues on Aim research report.
The fifth annual examination of the entire AIM market, detailing the fastest growing companies on the junior market, aswell as the most profitable and the least profitable businesses. Buy the Spotlight on AIM 2009 research report today.
Business XL, the award-winning monthly magazine for growing companies, is delighted to announce the launch of a new study on cash shells. The research provides a comprehensive overview of cash shells on AIM, companies that have become a significant feature on the AIM landscape. Buy Cash Shells 2009 Research Report today.
In the first ever deep analysis of trading values and volumes on AIM, Growth Company Investor, in association with BDO Stoy Hayward, will be shining their research light on the pre-eminent companies on AIM. Buy the Liquidity Drivers on AIM research report today.
Advertisement
Phil Edmonds’ African food group Agriterra expects a turnaround to profits as it contemplates a move into sugar.
‘Smart metering’ specialist Bglobal has obtained up to £15 million asset funding from Barclays Asset Sales & Finance.
Jubilee Platinum is offering shares to buy fellow AIM counter, smelting and refining specialist Braemore Resources.
